1. Case report
==============

Sinus node dysfunction is branded by ≥1 of the following electrocardiographic signs: sinus bradycardia, sinus arrest, sinoatrial block, and supraventricular tachycardia interchanging with sinus bradycardia and asystole (Brady-tachycardia syndrome).^\[[@R1]\]^ The existence of palpitations, dizziness, presyncope, or syncope related to these electrocardiographic modifications defines sinus node disease (SND). SND happens more frequently in women than in men, resulting in a high morbidity between 60 and 69 years.^\[[@R2],[@R3]\]^ The most common form of SND has no clear etiology and is considered idiopathic or primary.^\[[@R4],[@R5]\]^ Paroxysmal atrial fibrillation (AF) is common in subjects with sick sinus syndrome (SSS) and pacemakers and leads to morbidity and an increased risk of stroke or death.^\[[@R6]\]^ The standard treatment to SND is the pacemaker implantation,^\[[@R7]\]^ and the perfect line of attack for the management of AF is rhythm control, but this is sometimes very hard to accomplish.^\[[@R8]\]^ For such actions, complete isolation of all pulmonary veins (PVIs) is currently widely accepted as the best endpoint. The recommendations of the European Society of Cardiology (ESC) (Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the ESC).^\[[@R8]\]^ For the individual patient with symptomatic AF, there must be sufficient potential benefit to justify a complex ablation procedure associated with possibly severe complications. Operator experience is an important consideration when considering ablation as a treatment option. The studies cited in support of the recommendations have been almost exclusively performed by highly experienced operators and expert staff working in specialized institutions, but in clinical practice, more junior and less experienced operators may be involved in many institutions. Catheter ablation is usually undertaken in patients with symptomatic paroxysmal AF that is resistant to at least 1 antiarrhythmic drug. Catheter ablation for paroxysmal AF should be considered in symptomatic patients who have previously failed a trial of antiarrhythmic medication (Class IIa, Level A). Ablation of persistent symptomatic AF that is refractory to antiarrhythmic therapy should be considered a treatment option (Class IIa, Level B).

The unique issue, in this case, never described in the literature is the fact that the application of atrial radiofrequency for PVI diffused through the tissues, affecting in some way the tip of the ventricular electrode, causing a microlesion in this structure and making it impossible to capture the right ventricle by the pacemaker.

In this case, we presented a case of a female patient, 81 years old, with controlled hypertension, without coronary artery disease, bearer of bilateral knee replacement, and dual-chamber pacemaker implanted 1.5 years ago owing to sinus node disease, presenting the following symptoms: presyncope episodes associated with sustained irregular palpitation tachycardia. The evaluation of the pacemaker-recorded episodes of atrial fibrillation, the echocardiogram-presented normal systolic function and measurements, as well as the resting myocardial scintigraphy and with drug use did not demonstrate ischemia and/or fibrosis. The patient was in use of valsartan 320 mg daily, amlodipine 10 mg daily, sotalol hydrochloride 120 mg 2 times daily and dabigatran 110 mg 2 times daily (the ethics committee composed by Paola Baars Gomes Moises, Luis Marcelo Rodrigues Paz, Humberto Cesar Tinoco e Jonny Shogo Takahashi, approved the execution of the case). Informed consent was signed by the patient.

Before the AF ablation procedure, the pacemaker generator, the atrial and ventricular leads were presenting normal functioning. The patient was submitted to general anesthesia by an anesthesiologist, and 1 g of vancomycin was administered intravenously. She presented bicameral programmed artificial pacing rhythm. Under fluoroscopic vision, 4 right femoral vein punctures were performed, with 2sheaths 6F, one 7F, and another 12F. Through the sheath 12F, the Agilis NxT Steerable Introducer (St. Jude Medical) was inserted, and the sheath 8F was replaced by the long sheath Fast-Cath Transseptal Guiding Introducers SL-0 (St. Jude Medical). A left femoral vein puncture was performed with the introduction of a 10F sheath, through which the intracardiac echocardiography probe (ViewFlex Xtra Intracardiac Echocardiography; St. Jude Medical) was inserted, positioned in the lower right atrium. We performed 2 transeptal punctures using a 71- and 98-cm BRK Transseptal Needles (St. Jude Medical), respectively, and the right femoral artery was punctured, being inserted an 8F sheath to monitor invasive blood pressure. Electrosurgical plate and EnSite Velocity Cardiac Mapping System (St. Jude Medical) electrode for electroanatomical mapping were positioned on the patient. Right heart chambers' catheterization was performed, and left chambers' catheterization was also performed after double transeptal punctures, with the following catheter positions:A quadripolar fixed curve catheter was positioned at the tip of the right ventricleA decapolar dirigible catheter was positioned within the coronary sinusA decapolar dirigible circular catheter, in pulmonary veins and left atrium, alternatelyOne TactiCath Quartz Contact Force Ablation Catheter (St. Jude Medical), in the left atrium and pulmonary veins, alternately.

The long sheaths in the left atrium were maintained continuously irrigated with heparinized saline. Infusion of heparin was performed by an infusion pump, keeping the coagulation activated time \>300 seconds. The esophagus remained in the right retro-atrial midline. The electroanatomical map reconstruction of the left atrium and pulmonary veins by the EnSite Velocity Cardiac Mapping System (St. Jude Medical, USA) was performed, with subsequently electrical PVIs by TactiCath Quartz Contact Force Ablation Catheter (St. Jude Medical), as shown in Figure [1](#F1){ref-type="fig"}A--D. Radiofrequency applications were made in the antrum of the pulmonary veins of the left atrium, using the power of 35 W and maximum temperature of 42°C. Atrial and pulmonary intravein stimulation to check pulmonary vein inlet and outlet blockade confirmed the PVIs. New decrement atrial electrical stimulation at continuous cycles of 350 to 200 ppm did not induce sustained new arrhythmias, maintaining sinus rhythm. The total procedure time was approximately 1 hour.

![The electroanatomical map reconstruction of the left atrium and pulmonary veins by the EnSite Velocity Cardiac Mapping System (St. Jude Medical) was performed, with subsequently electrical isolation of the pulmonary veins by 2 views (A) and (B). Intracardiac left atrial signals showing the left superior pulmonary vein before the isolation (C) and after isolation (D).](medi-96-e7060-g001){#F1}

At the end of the procedure, the patient presented hemodynamic instability, with a decrease in heart rate to 30 bpm and invasive arterial blood pressure to 60/30 mmHg. The pericardial puncture was quickly carried out with the possibility of cardiac tamponade as the first hypothesis, but no pericardial effusion was found. Next, we detected acute capture loss from the ventricular pacemaker lead, unvarying with high voltage and pulse width, even with stable impedance, sense and keeping the same position visualized by fluoroscopy (Fig. [2](#F2){ref-type="fig"}B and C), and there was soon afterwards induction of sustained ventricular tachycardia degenerating to spontaneous ventricular fibrillation. Electrical cardioversion-defibrillation was performed with 200 J, and the sinus rhythm was reestablished, but there was a dead short, and the pacemaker generator was burned and disabled. We maintained the patient\'s heart continuously stimulated by the catheter positioned in the right ventricle at 80 ppm, and hemodynamically stable. The pacemaker system was extracted, and a new DDDR pacemaker generator (Assurity MRI Pacemaker; St. Jude Medical) was implanted (Fig. [3](#F3){ref-type="fig"}A--C). The atrial lead (Tendril MRI Pacing Lead; St. Jude Medical) was fixed into the right atrial appendage, and the ventricular lead (Tendril MRI Pacing Lead; St. Jude Medical) was positioned in the right ventricular high septum, with the following parameters, respectively:

![Right atrial and ventricular leads positioning inside the heart after pulmonary veins isolation, during pericardial puncture (A) and during pericardial contrast injection (B), and loss of capture by ventricular lead (C). We can observe that the ventricular lead position did not change.\\.](medi-96-e7060-g002){#F2}

![Stepwise leads extraction (A), (B), and the new pacemaker set implanted (C).](medi-96-e7060-g003){#F3}

P wave: 2.1 mV Impedance: 502 Ω Threshold: 0.75 V @ 0.5 ms

R wave: 9.9 mV Impedance: 650 Ω Threshold: 0.50 V @ 0.5 ms

After 48 hours, the patient was discharged, using the same medications; the symptoms were no longer present; no AF episodes were recorded by the pacemaker, and this one presented normal parameters. Until the present time of follow-up (1 month), the patient remained asymptomatic, without AF, and keeping normal pacemaker parameters. Evaluating backward stepwise the procedure, we observed that there was no displacement of the ventricular lead, no changes in its impedance and sense, but only the acute loss of ventricular capture occurred even programming the ventricular stimulation by the generator with high-voltage output and with large pulse width. So, we can speculate application of atrial radiofrequency for PVI diffused through the tissues, affecting in some way the tip of the ventricular electrode, causing a microlesion in this structure, and making it impossible to capture the right ventricle by the pacemaker. As we cannot see it, we can call it of phantom injury of the ventricular lead.
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